Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration

NCT00493220 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: SC HYLENEX and Ceftriaxone
DRUG: SC Placebo and Ceftriaxone
DRUG: IV Ceftriaxone

Sponsor

Baxter Healthcare Corporation

Collaborators

[object Object]